Autonomix Medical (AMIX) investor relations material

Executive summary

• Development-stage medical device company focused on neural sensing and RF ablation for nerve-targeted therapies, with initial application in pancreatic cancer pain management.

• Proprietary catheter-based system aims to improve precision and consistency in nerve ablation procedures, with potential expansion to other pain and cardiovascular indications.

• No product revenue to date; operations funded primarily through equity sales and warrant offerings.

• Accumulated deficit of $67.1 million as of March 31, 2026, with substantial doubt about ability to continue as a going concern without additional capital.

Financial highlights

• Net loss for the year ended March 31, 2026 was $16.7 million, compared to $11.4 million in the prior year.

• Operating expenses increased 47% year-over-year to $17.0 million, driven by higher R&D and G&A costs.

• Cash used in operating activities was $12.3 million, with $7.0 million in cash and $5.9 million in working capital at fiscal year-end.

• No revenue generated; funding primarily from $10.2 million in net financing activities, including equity and warrant issuances.

Outlook and guidance

• Current cash resources expected to fund operations into, but not beyond, Q4 2026; additional $25–$32 million needed to reach initial commercial launch.

• Planned U.S.-based clinical trials anticipated to begin in late 2026, contingent on new financing.

• Regulatory clearance targeted for 2028, subject to significant uncertainty.